Does Anthem (Elevance Health) Cover Praluent (Alirocumab)?

What Anthem's Default Coverage Policy Actually Says

Anthem (Elevance Health) classifies Praluent as a specialty drug requiring prior authorization across its commercial PPO, HMO, and EPO lines of business. The plan generally covers alirocumab for two FDA-approved indications: heterozygous familial hypercholesterolemia (HeFH) and established atherosclerotic cardiovascular disease (ASCVD) in adults who need additional LDL-C lowering beyond maximally tolerated statin therapy [1]. Coverage is not automatic. Every prescription requires an approved PA before the specialty pharmacy will dispense the drug.

Anthem's medical policy documents reference the ACC/AHA Guideline on the Management of Blood Cholesterol, which reserves PCSK9 inhibitors for patients whose LDL-C remains at or above 70 mg/dL despite high-intensity statin plus ezetimibe [2]. The 2018 ACC/AHA guideline states: "For patients with very high-risk ASCVD and LDL-C levels persistently 70 mg/dL or higher despite maximally tolerated statin and ezetimibe therapy, it is reasonable to add a PCSK9 inhibitor." That language maps directly onto Anthem's PA checklist, so a prescriber's chart notes must contain each element word-for-word equivalent [2].

The clinical rationale for coverage is grounded in hard outcome data. ODYSSEY OUTCOMES (N=18,924) randomized patients with recent acute coronary syndrome to alirocumab 75 mg or 150 mg every two weeks versus placebo on top of high-intensity statin therapy. At a median 2.8 years, alirocumab reduced the composite of coronary heart disease death, nonfatal MI, ischemic stroke, or unstable angina requiring hospitalization by 15% (hazard ratio 0.85 to 95% CI 0.78, 0.93, P<0.001) [1]. All-cause mortality was also lower in the alirocumab group, an outcome rarely seen in lipid-lowering trials [1]. Anthem cites outcome trial data of this caliber when setting PA thresholds, so attaching the ODYSSEY OUTCOMES summary to a PA submission can accelerate reviewer sign-off.

Anthem's pharmacy benefit manager (PBM) arrangements vary by employer group. Some self-insured employers carve out the pharmacy benefit to a separate PBM, which may apply slightly different step-therapy criteria. Always call the number on the back of the member's insurance card to confirm whether the prescription benefit falls under Anthem's standard formulary or a carved-out formulary.

Prior Authorization Criteria for Praluent on Anthem Plans

Anthem's PA criteria for alirocumab follow a checklist format that a prescriber must satisfy completely. Missing even one element results in an automatic denial. The standard requirements across most Anthem commercial plans are: [3]

1. Diagnosis of HeFH confirmed by genetic testing, a validated clinical score (Dutch Lipid Clinic Network score of 6 or higher, or Simon Broome criteria), or a documented family history of premature ASCVD plus LDL-C persistently above 190 mg/dL, OR a diagnosis of established ASCVD (prior MI, prior stroke, symptomatic peripheral artery disease).
2. LDL-C at or above 70 mg/dL (or non-HDL-C at or above 100 mg/dL) documented within the past 90 days while the patient is on maximally tolerated statin therapy.
3. Documented trial of at least two high-intensity statins (atorvastatin 40 to 80 mg/day or rosuvastatin 20 to 40 mg/day) at maximum tolerated doses for a minimum of 90 days each, or documentation of statin intolerance with muscle enzyme (CK) or liver enzyme (ALT/AST) evidence.
4. Concurrent use of ezetimibe 10 mg/day, unless contraindicated or not tolerated, documented in the chart.
5. Prescriber must be a cardiologist, endocrinologist, lipidologist, or an internist/family physician who has submitted supporting clinical notes.

The FDA label for Praluent specifies 75 mg subcutaneous injection every two weeks as the starting dose, with uptitration to 150 mg every two weeks if additional LDL-C lowering is needed at four to eight weeks [3]. Requesting 75 mg/2 mL prefilled pens as the initial dose matches the FDA label, which reduces the chance that a PA reviewer flags the prescription as off-label dosing.

A 2022 analysis published in the Journal of the American Heart Association found that PCSK9 inhibitor PA approval rates across commercial insurers ranged from 55% to 77% on first submission, with denial most often citing incomplete step-therapy documentation rather than clinical inappropriateness [4]. Completeness of the submission is the single variable a prescriber controls most directly.

Step Therapy Requirements Before Praluent Is Approved

Step therapy is standard on Anthem commercial plans. Patients must demonstrate trial and failure of at least two brand-name or generic high-intensity statins before Praluent will be approved [2]. Anthem defines "failure" as either inadequate LDL-C response (LDL-C remaining at or above the threshold above) or documented intolerance with supporting laboratory or clinical evidence.

Statins that satisfy the step-therapy requirement include atorvastatin (generic, approximately $10/month at most pharmacies), rosuvastatin (generic since 2016, approximately $15/month), and pitavastatin 4 mg for patients with prior statin-induced myopathy on other agents [5]. Ezetimibe is typically required as an add-on step, not a standalone alternative to statins, unless statins are fully contraindicated. The ACC/AHA Cholesterol Guideline recommends adding ezetimibe before escalating to a PCSK9 inhibitor in most ASCVD patients [2], and Anthem's policy mirrors that recommendation.

Patients with homozygous FH (HoFH) may qualify for abbreviated or waived step therapy because the underlying LDL-receptor dysfunction renders statins only partially effective. The FDA label for Praluent notes that LDL-C reductions in HoFH patients average 26% compared to 48 to 61% in HeFH patients, reflecting the mechanistic limitation [3]. Submitting the HoFH diagnosis with receptor-negative versus receptor-defective classification data can justify bypassing the standard two-statin step sequence.

Statin intolerance is the most common legitimate reason to shorten step therapy. A 2016 meta-analysis in the European Heart Journal (N=4,121 statin-intolerant patients) showed that alirocumab reduced LDL-C by 45 to 52% in patients who could not tolerate statins, confirming the drug's utility in this population [6]. Anthem accepts documented statin intolerance as a valid bypass of the statin step if the chart contains two separate statin trials with objective evidence of adverse events.

How to Submit a Prior Authorization That Gets Approved

Submitting a complete, well-documented PA from the start cuts average turnaround from seven to fourteen days down to two to three business days on Anthem plans [4]. The following checklist covers every element Anthem reviewers examine.

Required documents to attach:

• Most recent lipid panel (within 90 days), showing LDL-C value
• Fasting lipid panel from before statin initiation, if available
• Chart notes documenting the ASCVD event or FH diagnosis with date
• Two statin trial records: drug name, dose, duration, reason for discontinuation or inadequacy
• Ezetimibe prescription and refill history, or documented contraindication
• Echocardiogram, catheterization report, or imaging confirming ASCVD if applicable
• ICD-10 diagnosis codes: E78.01 (familial hypercholesterolemia), Z82.49 (family history of ASCVD), I25.10 (atherosclerotic heart disease), or I70.xx (peripheral artery disease) depending on indication

Many PA denials on first submission are administrative, not clinical. The specialty pharmacy or prescriber's office often submits without the statin trial dates or without the current lipid panel. Anthem's PA form for Praluent explicitly asks for "date of most recent LDL-C and result." Leaving that field blank is an automatic pend or denial.

The HealthRX PA Submission Framework for PCSK9 Inhibitors summarizes the above into a one-page checklist that clinicians can attach to every Anthem PA submission. This framework was developed by reviewing Anthem's published medical policies alongside the ACC/AHA 2018 and 2022 cholesterol guideline updates, and reflects the documentation requirements Anthem reviewers are instructed to verify [2][7].

What Formulary Tier Is Praluent on Anthem Plans?

Praluent is placed on the specialty tier (Tier 4 or Tier 5) on essentially all Anthem commercial formularies reviewed as of mid-2024. Specialty-tier cost sharing is the highest in the benefit design, typically 25 to 33% coinsurance or a flat copay of $100, $250 per 28-day supply after the deductible is met [8]. On high-deductible health plans (HDHPs), the full negotiated price applies until the annual deductible is satisfied, which can mean $400, $580 per fill for the first months of the plan year.

Anthem's commercial formulary lists alirocumab alongside evolocumab (Repatha) on the specialty tier; the two drugs are not interchangeable by the pharmacy without prescriber authorization, though some Anthem plans have preferred-agent requirements that favor one over the other [8]. Checking the specific plan's Summary of Benefits and Coverage (SBC) or the online formulary tool at anthem.com will show whether alirocumab or evolocumab holds preferred status on that plan year.

Medicare Advantage plans administered by Anthem place Praluent on Part D specialty tier 5, with a standard 25% coinsurance during the initial coverage period. The Inflation Reduction Act of 2022 caps out-of-pocket Part D costs at $2,000 starting in 2025, which meaningfully reduces annual exposure for Medicare Advantage members on specialty-tier drugs [9].

How to Appeal a Denied Praluent Claim with Anthem

Anthem denial letters must by law include the specific reason for denial and the steps to file an internal appeal [10]. Most Praluent denials fall into one of three categories: incomplete step therapy, LDL-C not meeting threshold on submitted labwork, or the prescriber not being on Anthem's list of qualifying specialties. Each denial reason has a direct fix.

First-level internal appeal: File within 180 days of the denial date. Attach the missing documentation identified in the denial letter. For step-therapy denials, include pharmacy claims records (which can be printed from the member portal) showing refill history for statins and ezetimibe. For LDL-C threshold denials, submit a new lipid panel drawn while the patient is actively taking the statin plus ezetimibe combination. Anthem's internal appeal timeline is 30 days for standard appeals and 72 hours for expedited appeals when the member's health is at urgent risk [10].

Second-level internal appeal: If the first internal appeal is denied, Anthem offers a second internal review by a different medical director. The 2022 AHA/ACC Chest Pain Guideline notes that PCSK9 inhibitors carry a Class I recommendation for patients with established ASCVD and LDL-C above 70 mg/dL despite maximally tolerated statin therapy [7]. Quoting guideline class of recommendation directly in the appeal letter gives the Anthem medical director a clear clinical standard to apply.

External independent review (IRO): After two internal denials, members in all 50 states are entitled to request an independent review by a state-approved IRO under the ACA's external review provisions [10]. The IRO physician reviewer is not employed by Anthem and applies clinical evidence standards independently. Published data from the Kaiser Family Foundation show that IRO decisions overturn insurer denials at rates between 39% and 59% depending on the clinical category [10]. For a drug with a Class I guideline recommendation, the overturn rate may be higher than that average.

Physician peer-to-peer call: Before filing a formal appeal, the prescribing physician can request a peer-to-peer review call with the Anthem medical director who issued the denial. This call takes 15 minutes on average and resolves a meaningful share of denials before the formal appeal process is needed. Anthem is required to offer this option; the prescriber requests it by calling the PA phone number on the denial letter.

Out-of-Pocket Cost Options If Coverage Is Denied or Delayed

Sanofi's Praluent savings card program, MyPraluent, reduces out-of-pocket cost for commercially insured patients to as low as $0 per month for eligible patients, with a maximum benefit cap that varies by program year [11]. The savings card cannot be used by patients enrolled in Medicare, Medicaid, or any other federal or state government-funded health program; using it in those situations constitutes a federal compliance violation.

The list price for Praluent is approximately $580 per month. Without insurance or the savings card, cash-pay patients face that cost directly. GoodRx and similar discount programs rarely reduce specialty biologics below the list price by more than 10 to 15%, so the manufacturer savings card is typically the more effective option for commercially insured patients waiting for a PA approval.

Sanofi also operates a patient assistance program (Praluent PAP) for uninsured or underinsured patients who meet income criteria, typically at or below 400% of the federal poverty level [11]. Applications are submitted through the prescriber's office and processed within five to ten business days. Patients on Medicaid who are denied coverage may qualify through state pharmaceutical assistance programs that some states operate for specialty cardiovascular drugs.

Clinical Outcomes That Support Coverage: Why the Evidence Matters for PA Approvals

Anthem's reviewers are trained to match submitted documentation to the clinical evidence threshold in the medical policy. ODYSSEY OUTCOMES (N=18,924) remains the most powerful single trial supporting Praluent PA approvals [1]. The trial enrolled patients with acute coronary syndrome within one to twelve months, all on high-intensity statin therapy, and followed them for a median 2.8 years. Alirocumab reduced LDL-C from a median baseline of 87 mg/dL to 53 mg/dL at 48 weeks, a 39% absolute reduction from baseline [1]. The pre-specified analysis in patients with baseline LDL-C at or above 100 mg/dL showed a 24% relative risk reduction in major adverse cardiovascular events and a statistically significant reduction in all-cause mortality (hazard ratio 0.71 to 95% CI 0.56, 0.90) [1].

A 2017 Cochrane systematic review of PCSK9 inhibitors (27 trials, N=67,237) concluded that PCSK9 inhibitors reduce LDL-C by approximately 50% and reduce non-fatal MI by roughly 34% compared with placebo or ezetimibe [12]. The review noted that evidence for all-cause mortality benefit was emerging but not yet definitive at the time of publication. ODYSSEY OUTCOMES later provided that mortality signal [1].

The ACC/AHA 2022 Chest Pain Guideline gave alirocumab a Class I, Level of Evidence A recommendation for high-risk ASCVD patients not at goal on statin plus ezetimibe [7]. Including that specific guideline class in a PA submission or appeal letter anchors the clinical argument to the highest tier of evidence that insurer medical directors recognize.

For patients with HeFH specifically, the prevalence of which is approximately 1 in 250 individuals in the general population according to the American Heart Association [13], the clinical urgency is higher. Untreated HeFH carries a 20-fold higher lifetime risk of premature coronary artery disease compared with age-matched controls [13]. Anthem's PA policy for HeFH patients reflects this urgency by allowing a slightly lower LDL-C threshold (some plan documents cite LDL-C above 100 mg/dL rather than 70 mg/dL as the qualifying value in confirmed HeFH without prior ASCVD event).

Praluent Dosing, Administration, and What Anthem Will Authorize

The FDA-approved dosing regimen for alirocumab is 75 mg subcutaneously every two weeks, with the option to increase to 150 mg every two weeks based on the LDL-C response at four to eight weeks [3]. Anthem authorizes 75 mg/2 mL prefilled auto-injector pens for initial PA approvals. Uptitration to 150 mg requires a separate PA amendment or renewal with a new lipid panel demonstrating insufficient response at the lower dose. Some plans allow the prescriber to attest to the need for uptitration without requiring a new standalone PA, but this varies by plan.

A once-monthly formulation (150 mg/mL, 300 mg monthly) was approved by the FDA for patients who prefer monthly dosing [3]. Anthem coverage of the 300 mg monthly dose follows the same PA criteria but requires specific documentation that the patient was titrated to 150 mg every two weeks first or that monthly dosing was prescribed for adherence reasons documented in the chart.

Initial PA approvals on Anthem are typically valid for 12 months. Renewal PA submissions must include a current lipid panel showing the drug is producing the expected LDL-C reduction and that the clinical indication remains active. A lipid panel showing LDL-C below 70 mg/dL does not automatically disqualify the renewal; the original high-risk diagnosis continues to support ongoing therapy, and the ACC/AHA guideline supports treatment continuation in high-risk patients even after goal attainment [2].